ReviewCurrent oncology (Toronto, Ont.)2018
Advanced typical and atypical carcinoid tumours of the lung: management recommendations.
Review in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Yttrium-90 Radioembolization Versus Transarterial Embolization for Lung Carcinoid Hepatic Metastasis.JTO clinical and research reports · 2026Article
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids.Endocrine · 2025Article
- Neuroendocrine Neoplasms of the Lungs, Thyroid, and Thymus.Biomedicines · 2025Review
- A case of carcinoid syndrome after CT guided lung biopsy of a neuroendocrine tumor.Radiology case reports · 2024Article
- Article
- Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy.Cancer nanotechnology · 2023Review
- Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors.Molecular and clinical oncology · 2022Article
- Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.International journal of molecular sciences · 2022Article
- Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report.Respirology case reports · 2022Article
- Cushing syndrome secondary to a mediastinal carcinoid tumor: a case report.International cancer conference journal · 2022Article
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.Pathologica · 2021Review
- Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review.Molecular and clinical oncology · 2021Article
- Article
- Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based onEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Diagnosis and management of small pulmonary atypical carcinoid tumor associated with Cushing syndrome.Lung cancer management · 2020Article
- Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report.Molecular and clinical oncology · 2020Article
- Review
- miR375-3p Distinguishes Low-Grade Neuroendocrine From Non-neuroendocrine Lung Tumors in FFPE Samples.Frontiers in molecular biosciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroendocrine tumours (nets) are classified by site of origin, with lung being the second most common primary site after the gastrointestinal tract. Lung nets are rare and heterogeneous, with varied pathologic and clinical features. Typical and atypical carcinoid tumours are low-grade lung nets which, compared with the more common high-grade nets, are associated with a more favourable prognosis. Still, optimal treatment strategies are lacking. Methods: This review concentrates on classification and treatment strategies for metastatic low-grade lung nets, considering both typical and atypical carcinoids. The terminology can be confusing, and an attempt is made to simplify it. Promising results from recent trials that included lung nets are presented and discussed. Finally, guidelines from Europe and North America are discussed, and differences are noted. Results: Even within the group of patients with low-grade nets, the presentation, the locations of metastasis, and the speed of progression can be very different. The initial work-up and an understanding of the tumour's biology are key in making management decisions. Various treatment options-including somatostatin analogs, peptide receptor radioligand therapy, and biologic systemic therapy, specifically with the mtor (mechanistic target of rapamycin) inhibitor everolimus-are now available and are presented in a treatment algorithm. Summary: Although lung nets are rare and evidence supporting optimal treatment strategies is lacking, the recent publication of trials that have included patients with lung nets advances evidence-based therapy for these tumours. Many variables have to be considered in managing these tumours that have received little attention. Education for treating physicians is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.